1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Supplemental Filings: Back To US FDA’s Conference Center, What Marks Wants In A Gene Therapy Director, And More

 
• By Pink Sheet Team

Short stories about how US FDA’s conference center changed since COVID-19 forced the end of in-person public events, what the agency did to officially close the books on Makena, and more.

GDUFA regulatory science priorities meeting
The FY 2023 generic drug regulatory science priorities meeting at the US FDA seemed familiar. • Source: Derrick Gingery

Welcome to another edition of Supplemental Filings, where US-based Pink Sheet reporters offer bonus, quick-hit analysis and insights we think you should know about, but didn’t make it into full-length stories.

The COVID-19 pandemic may have forced a lot of changes in society, but the US Food and Drug Administration’s conference...

More from US FDA

More from Agency Leadership